Reliable molecular biomarkers are important for the diagnosis of diabetes and the development of novel drugs. Ace Therapeutics provides comprehensive diabetes-related molecular biomarker development services. With our multi-omics technology and advanced bioinformatics analysis, we are committed to providing our clients with one-stop solutions from marker discovery to preclinical validation.

Introduction to Diabetes-Related Molecular Biomarkers

Diabetes mellitus is a complex metabolic disease associated with disturbances in the metabolism of carbohydrates, lipids and proteins. The identification of new molecular biomarkers can help to better understand the pathogenesis involved in diabetes and can support early diagnosis and drug development for diabetes. Among various molecular biomarkers, proteomic biomarkers and miRNAs have emerged as promising biomarkers for diabetes diagnosis and drug development. These molecules play key roles in various cellular pathways involved in the pathogenesis of diabetes.

Our Diabetes-Related Biomarker Development Services

• Diabetes-related molecular biomarker discovery services

We help our clients screen and validate potential biomarkers using advanced histological techniques and bioinformatics analysis. From sample collection, data analysis to marker validation, we provide one-stop services dedicated to the discovery of key molecular markers for diabetes diagnosis, pathogenesis and personalized treatment.

• Diabetes-related molecular biomarker validation services

In the validation session, we use a variety of high-precision detection technologies to accurately detect and analyse both small and large molecule biomarkers.

Our Biomarker Development Technologies

• Lipidomics: We comprehensively analyze changes in lipid metabolism in our clients' samples through lipidomics technology. In addition, we combine high-throughput mass spectrometry assays and bioinformatics analyses to screen and validate differential lipid molecules associated with diabetes, helping our clients identify potential molecular markers.
• Genomics: Identification of mutations, single nucleotide polymorphisms (SNPs) and differentially expressed genes associated with diabetes by whole genome sequencing (WGS) and transcriptome sequencing (RNA-seq).
• Metabolomics: We use liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) techniques to analyse metabolite profiles and the metabolic pathways they participate in, and to discover metabolic markers associated with diabetes.
• Proteomics: We use mass spectrometry (MS) to quantify protein expression profiles in diabetes-related tissues, revealing key proteins and their functional changes.

Ace Therapeutics' Biomarker Lab supports method development and validation of diabetes-related molecular biomarkers with cutting-edge technologies and customized solutions. Please contact us for more details and we will be happy to assist you.

References

1. Zarch, S. M. A.; et al. Molecular biomarkers in diabetes mellitus (DM). Medical journal of the Islamic republic of Iran. 2020, 34: 28.
2. Lees, T.; et al. Recent advances in molecular biomarkers for diabetes mellitus: a systematic review. Biomarkers. 2017, 22(7): 604-613.

• Glucose-Related Biomarker Development Services
• Insulin Resistance-Related Biomarker Development Services
• Tissue Biomarker Development Services for Diabetes
• Biomarkers Development Services of Vascular Function in Diabetes

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators